No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfection products, personal protective equipment, as well as formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
www.yiling.cnNo one on the platform currently holds 002603.SZ.
No tracked institution reports a position in 002603.SZ as of their last filing.
No one on the platform has traded 002603.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.2% | — | — | — | ||
| Rev. Growth % | 20.2% | -2.3% | ||||
| Profit Margin % | 16.4% | 10.1% | 11.4% | |||
| Free Cash Flow Margin % | 19.5% | 9.5% | 4.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $8.4B | +3.6% | $0.90 | $0.87–$0.92 | — | 1 |
| 2027 | $9.0B | +7.2% | $1.04 | $1.01–$1.07 | — | 1 |
| 2028 | $9.4B | +4.7% | $1.23 | $1.19–$1.27 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002603.SZShijiazhuang Yiling Pharmaceutical Co., Ltd. | $15.15 | -0.33% | $25.3B | — |
| 000423.SZDong-E-E-Jiao Co.,Ltd. | $45.94 | -0.37% | $29.4B | — |
| 002007.SZHualan Biological Engineering Inc. | $12.76 | -0.78% | $23.3B | — |
| 002773.SZChengdu Kanghong Pharmaceutical Group Co., Ltd | $19.14 | +0.05% | $17.6B | — |
| 002821.SZAsymchem Laboratories (Tianjin) Co., Ltd. |
| $180.88 |
| +2.08% |
| $60.2B |
| — |
| 600161.SSBeijing Tiantan Biological Products Co., Ltd. | $12.02 | -1.31% | $23.8B | — |
| 600329.SSTianjin Pharmaceutical Da Ren Tang Group Corporation Limited | $34.16 | +0.23% | $19.5B | — |
Source: Financial Modeling Prep · peers by sector/industry